title: Eculizumab and refractory membranoproliferative glomerulonephritis.
authors.forename: Seetha
authors.initials: S
authors.lastname: Radhakrishnan
authors.forename: Andrew
authors.initials: A
authors.lastname: Lunn
authors.forename: Michael
authors.initials: M
authors.lastname: Kirschfink
authors.forename: Paul
authors.initials: P
authors.lastname: Thorner
authors.forename: Diane
authors.initials: D
authors.lastname: Hebert
authors.forename: Valerie
authors.initials: V
authors.lastname: Langlois
authors.forename: Fred
authors.initials: F
authors.lastname: Pluthero
authors.forename: Christoph
authors.initials: C
authors.lastname: Licht
mesh_terms: D000293:Adolescent; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D003176:Complement C3 / Q000032:analysis; D003182:Complement C5 / Q000037:antagonists & inhibitors* / Q000276:immunology; D015938:Complement Membrane Attack Complex / Q000032:analysis; D003404:Creatinine / Q000097:blood; D005260:Female; D015432:Glomerulonephritis, Membranoproliferative / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000276:immunology / Q000473:pathology; D000069283:Rituximab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D003176:Complement C3; D003182:Complement C5; D015938:Complement Membrane Attack Complex; D000069283:Rituximab; C481642:eculizumab; D003404:Creatinine